US 11,987,633 B2
Cross-species-specific single domain bispecific single chain antibody
Peter Kufer, Munich (DE); Tobias Raum, Munich (DE); Roman Kischel, Munich (DE); Ralf Lutterbüse, Munich (DE); Patrick Hoffmann, Munich (DE); Matthias Klinger, Munich (DE); Doris Rau, Munich (DE); and Susanne Mangold, Munich (DE)
Assigned to AMGEN RESEARCH (MUNICH) GMBH, Munich (DE)
Filed by AMGEN RESEARCH (MUNICH) GMBH, Munich (DE)
Filed on Mar. 17, 2021, as Appl. No. 17/204,166.
Application 17/204,166 is a continuation of application No. 13/122,280, granted, now 10,981,998, previously published as PCT/EP2009/062795, filed on Oct. 1, 2009.
Claims priority of provisional application 61/101,935, filed on Oct. 1, 2008.
Prior Publication US 2022/0041736 A1, Feb. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/2863 (2013.01) [C07K 16/2803 (2013.01); C07K 16/2878 (2013.01); C07K 16/2884 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01)] 27 Claims
 
1. A nucleic acid comprising a polynucleotide encoding a bispecific single chain antibody molecule comprising a first binding domain which binds to an epitope of a human CD3 epsilon (CD3ε) chain, wherein the epitope is part of the amino acid sequence set forth in SEQ ID NO: 2, 4, 6, or 8, and comprises at least the amino acid sequence Gln-Asp-Gly-Asn-Glu (QDGNE; SEQ ID NO: 430), and a second binding domain comprising an antibody variable domain that is cross-species specific and binds to an epitope of a human and a non-chimpanzee primate tumor target antigen, wherein the first binding domain is a VHH domain and comprises CDR 1 of SEQ ID NO: 398, CDR 2 of SEQ ID NO: 399 and CDR 3 of SEQ ID. NO: 400.